Related Experiment Video

Updated: Apr 23, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

Republished: new age of biological therapies in paediatric rheumatology

Ethan S Sen1, A V Ramanan1

  • 1Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK.

Postgraduate Medical Journal
|September 19, 2014
PubMed

Insights

Biologic drugs offer revolutionary treatments for paediatric rheumatic diseases like juvenile idiopathic arthritis (JIA), leading to inactive disease and reduced long-term damage. Novel agents are emerging, enhancing therapeutic options for children.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Paediatric rheumatic diseases stem from immune system dysregulation.
  • Biologic drugs target specific immune molecules like cytokines.
  • Significant advancements in treating juvenile idiopathic arthritis (JIA) have occurred.

Purpose of the Study:

  • To review recent evidence on biologic drug trials for systemic JIA, juvenile dermatomyositis, and juvenile systemic lupus erythematosus.
  • To highlight novel biologic agents under investigation for paediatric rheumatic diseases.
  • To emphasize the importance of clinical trials and registries for drug development.

Main Methods:

  • Review of recent clinical trials on biologic drugs.
  • Analysis of evidence for systemic JIA, juvenile dermatomyositis, and juvenile SLE.
  • Discussion of emerging novel therapeutic agents.

Main Results:

  • Biologic drugs have revolutionized treatment for paediatric rheumatic diseases, particularly JIA.
  • Achieving inactive disease and minimizing long-term damage is increasingly feasible.
  • Novel agents show promise for future therapeutic strategies.

Conclusions:

  • Biologic therapies represent a paradigm shift in managing paediatric rheumatic diseases.
  • Ongoing research and clinical trials are crucial for developing new treatments.
  • International collaboration through registries is vital for safety monitoring.

More Related Videos

Development of Recombinant Proteins to Treat Chronic Pain10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.2K
Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation10:15

Conditional Reprogramming of Pediatric Human Esophageal Epithelial Cells for Use in Tissue Engineering and Disease Investigation

Published on: March 22, 2017

6.5K

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
863
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
398
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
394
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
941